Ad-hoc | 3 May 2013 11:05
STADA Arzneimittel AG / Key word(s): Miscellaneous
03.05.2013 11:05
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Bad Vilbel, May 3, 2013 - In accordance with a contract signed today, Dr.
Matthias Wiedenfels (40) is to become Chief Corporate Development & Central
Services Officer which includes the areas Human Resources, Legal,
IP/Patents, Compliance, Risk Management and Export Control at STADA
Arzneimittel AG. Dr. Wiedenfels will take up his Executive Board duties
today. The Supervisory Board has appointed him as Executive Board member
until December 31, 2016.
Dr. Wiedenfels studied law and from 2002 initially worked as a lawyer in an
international corporate law firm. At STADA, Dr. Wiedenfels initially
assumed the position as Head of the Legal Department and General Counsel
from 2009 and already just a short time after that also assumed
responsibility for the Patent and Human Resources departments. In 2010, Dr.
Wiedenfels also became Chief Compliance Officer. Since 2011, his
responsibilities have also included Group Risk Management. In addition, Dr.
Wiedenfels has also held various management positions at individual local
subsidiaries. Most recently, Dr. Wiedenfels played already a part in all
important Group decisions as Senior Vice President.
With the appointment of Dr. Wiedenfels, STADA's Executive Board expands to
four members. This is a reflection of the increased size of the company and
the corresponding increase in the number of tasks for the individual
members of the Executive Board.
The Executive Board of STADA Arzneimittel AG thus now consists of Hartmut
Retzlaff, Chairman of the Executive Board, Helmut Kraft, Chief Financial
Officer, Dr. Axel Müller, Chief Production & Development Officer as well as
Dr. Matthias Wiedenfels, Chief Corporate Development & Central Services
Officer.
The Executive Board contract of Dr. Wiedenfels is based - as are the
contracts of the other three members of the Executive Board - on a
standardized compensation structure in line with the new legal requirements
from the Law for the Appropriateness of Executive Board Remuneration
(VorstAG) that has been approved by STADA's Annual General Meeting 2011.
Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail:
communications@stada.de /
Or visit us in the Internet at www.stada.com.
03.05.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------